antidiabetic medications l.
Skip this Video
Loading SlideShow in 5 Seconds..
Antidiabetic Medications PowerPoint Presentation
Download Presentation
Antidiabetic Medications

Loading in 2 Seconds...

play fullscreen
1 / 36

Antidiabetic Medications - PowerPoint PPT Presentation

  • Updated on

Antidiabetic Medications. Pharm 585 February 15, 2011 Hy N Dang. Goal. To understand the use and side effects of anti-diabetic medications and be able to educate patients. Nine to Know The minimum that every pharmacist must know about drugs!. Brand & Generic Name Mechanism of action

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

Antidiabetic Medications

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
    Presentation Transcript
    1. Antidiabetic Medications Pharm 585 February 15, 2011 Hy N Dang

    2. Goal To understand the use and side effects of anti-diabetic medications and be able to educate patients.

    3. Nine to KnowThe minimum that every pharmacist must know about drugs! • Brand & Generic Name • Mechanism of action • Therapeutic effect • Relevant pharmacokinetics and pharmacodynamics • Dosing by route • Adverse reactions and contraindications • Monitoring parameters • Drug-drug and drug food interactions • Comparisons between agents w/in the same class of drugs

    4. Contraindications/Cautions/Adverse Reactions • Adverse Reactions • Unwanted side effects: need to warn patient • Cautions • Warnings for clinicians to be aware when using medication. • Contraindications • Conditions which will render the medication absolutely unusable in that patient population

    5. Type 2 Diabetes High blood glucose Impaired GI motility • Defective beta cell function • Diminished phase 1 insulin release • Delayed phase 2 insulin release • 2. Overproduction of glucagon • Tissues less sensitive to insulin • Liver produces excess glucose Type 2 Video from Image Obtained From: Diabetes 101: Overview of Drug Therapy by Jennifer Danielson, RPh, CDE

    6. Biguanides Indication Type II Diabetes Mellitus, Antipsychotic-induced weight gain MOA Decrease hepatic glucose production, decrease intestinal absorption of glucose and increase insulin sensitivity therefore increasing peripheral glucose uptake

    7. Where does it work? Image Obtained From: Diabetes 101: Overview of Drug Therapy by Jennifer Danielson, RPh, CDE

    8. Biguanides (cont) Patient Info • N/V/D • Upset stomach/dyspepsia – take with food • Metallic taste • Minimal Weight Loss • Alcohol may increase likelihood of lactic acidosis • Does not cause hypoglycemia

    9. Biguanides (cont) Special Population Considerations: • Geriatric: limited data suggests starting doses should be 33% lower for geriatric patients than that of an adult dose. Titration should also to a lower limit. Cautions/Severe Adverse Reactions • Black Box Lactic Acidosis: D/C immediately and notify practitioner if: myalgia, malaise, hyperventilation, unusual somnolence. Alcohol potentiates this reaction. Advise patients not to consume excessive amounts of alcohol.

    10. Biguanides (cont) CONTRAINDICATIONS • Renal disease or renal dysfunction (Scr > 1.5 mg/dL in males, >1.4 mg/dL in females) • Abnormal Scr from any cause including: shock, acute MI, or septicemia • Metabolic acidosis (including diabetic ketoacidosis (DKA)) • Heart failure requiring pharmacologic therapy; active liver failure

    11. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Indications Diabetes Mellitus Type II MOA Inhibits the breakdown of GLP-1 by DPP-4 therefore increasing GLP-1 levels resulting in increased glucose-dependent insulin release and decreased level of circulating glucagon and hepatic glucose production

    12. Where does it work? Image Obtained From: Diabetes 101: Overview of Drug Therapy by Jennifer Danielson, RPh, CDE

    13. DPP-4 (cont) Patient Info • N/V • Hypoglycemia • Weight neutral • Nasopharyngitis/URI • Headache • Onset: Reduction in postprandial serum glucose: 60 minutes

    14. DPP-4 (cont) Special Population Considerations: • Renal Impairment: avoid combo drugs w/ metformin • For sitagliptin: • CrCl 30-50 mL/min : 50 mg daily • CrCl < 30 mL/min: 25 mg daily • End Stage Renal Disease Requiring dialysis: 25 mg daily • Geriatric: caution due to age related renal function decreases Cautions/Severe Adverse Reactions • Acute pancreatitis • Rash (Stevens-Johnson syndrome)

    15. Sulfonylureas Indications Adjuncts to diet and exercise to lower blood glucose in patients w/ type II diabetes mellitus MOA Stimulating insulin release from beta-cells of pancreatic islets

    16. Where does it work? Image Obtained From: Diabetes 101: Overview of Drug Therapy by Jennifer Danielson, RPh, CDE

    17. Sulfonylureas (cont) Patient Info • Hypoglycemia • GI upset/abdominal pain • Dizziness • Weight gain • Heartburn/epigastric fullness • Possible disulfiram-like reaction with alcohol (mainly w/ glyburide) • Onset: glucose lowering effect: 30 minutes with peak at 1.5-3 hours lasting 24 hours

    18. Sulfonylureas (cont) Special Population Considerations: • Pediatric: safety and efficacy not established for pts under age 16 • Hepatic/Renal Dysfunction: conservative dosing and titration recommended. Caution/Severe Adverse Reactions • Syndrome of Inappropriate Anti-diuretic Hormone (SIADH) CONTRAINDICATIONS • Diabetes complicated by ketoacidosis • Type I DM • Diabetes w/ pregnancy. Pregnancy Cat: C (except glyburide: B)

    19. Thiazolidinediones (TZD) Indications As adjunct to diet and exercise for type II diabetes MOA Increase insulin sensitivity by affecting PPAR-γ (peroxisome proliferators-activated receptor) at adipose tissue, skeletal muscle and in the liver. Special AlertFebruary 2011: Addition of Risk Evaluation and Mitigation Strategy to rosiglitazone. The medication is restricted to those patients already on rosiglitazone for fails pioglitazone or cannot be managed by other oral antidiabetic medications.

    20. Where does it work? Image Obtained From: Diabetes 101: Overview of Drug Therapy by Jennifer Danielson, RPh, CDE

    21. TZD (cont) Patient Info • Weight gain • Edema • Hypoglycemia esp. when used with other antidiabetic medications and insulin (not w/ metformin) • May cause or exacerbate heart failure with risk of fluid retention • URI, sinusitis, pharyngitis • Myalgia • Headache

    22. TZD (cont) Cautions/Severe Adverse Reactions • Black Box: Heart Failure (for all thiazolidinediones, mainly due to rosiglitazone) • Hepatic failure • Anemia • Bone loss • Ovulation in premenopausal women • Pregancy Cat: C

    23. TZD (cont) Special Populations Considerations: • Congestive Heart Failure: should be initiated at lowest approved dose with longer intervals between dose increases for NYHA class II. Use is not recommended in patients with NYHA Class III or IV CHF CONTRAINDICATIONS • NYHA Class III-IV heart failure • Active liver disease (ALT > 2.5 upper limit of normal)

    24. Insulin Indications Type I diabetes mellitus, type II diabetes mellitus, hyperkalemia, DKA/diabetic coma MOA Stimulating peripheral glucose uptake and inhibiting hepatic glucose production Patient Info • Hypoglycemia (BG < 70 mg/dL) esp with higher doses • Anxiety, blurred vision, palpitations, shakiness, slurred speech, sweating • Weight gain

    25. Where does it work? Image Obtained From: Diabetes 101: Overview of Drug Therapy by Jennifer Danielson, RPh, CDE Insulin: the Movie from

    26. Insulin (cont) Administration: • Subcutaneous injection • Rotate site • Check blood sugars regularly Storage: • Refrigerate until use • Once vial is punctured, it is good for 28 days and can be left at room temperature (except for glargine which is 90 days)

    27. Insulin (cont) Dosing: • Starting daily dose: 0.5-1 unit/kg/day in divided doses • Adjust according to fasting (premeal) blood glucose of 80-130 mg/dL and peak postprandial blood glucose < 180 mg/dL • Provide 50% as long acting insulin and 50% as prandial insulin • 1 unit of can account for 30 grams of carbohydrate (14-50) • 1 unit can lower 50 mg/dL blood glucose (10-100) Special Population Consderations: • Renal dysfunction • CrCl 10-50 mL/min: 75% of normal dose • CrCl < 10 ml/min: 25-50% of normal dose; monitor closely • Exercise??? ---- Acute Stress???

    28. Insulin Action Rapid/immediate Intermediate Fast Blood concentration Slow 0 2 4 6 8 10 12 14 16 18 20 22 24 Time (hr)

    29. Long-acting Long-acting & Short-acting Normal insulin secretion 70/30 pre-mixed Insulin Dosing

    30. Insulin Administration Pharmacology for Technicians by Ballington, Lauglin. EMC Paradigm 2006, Fig. 14.9

    31. Insulin (cont) Cautions/Severe Adverse Reactions • Severe hypoglycemia (seizure/coma) (BG < 40 mg/dL) • Edema • Lipoatrophy or lipohypertropy at injection site CONTRAINDICATIONS • Severe hypoglycemia • Allergy or sensitivity to any ingredient of the product

    32. Insulin Comparison Chart

    33. Adjunctive Therapy in Diabetes Mellitus Type II • Hypoglycemia • Complication of treatment! • Make sure patients inform the people around them of these symptoms and what to do! • Symptoms: Anxiety, blurred vision, palpitations, shakiness, slurred speech, sweating • Treatment: glucose/simple sugars: 3-4 glucose tablets, ½ can of soda (NOT diet!) • Treatment: glucagon injection • Dose: 1 mg IM, IV, SQ; may repeat in 20 minutes if needed

    34. Adjunctive Therapy (cont) Energy balance, diet, exercise • Low-carb, low-fat, calorie-restricted diet is recommended Cardiovascular disease/Hypertension • Systolic blood pressure goal < 130 mm Hg • Angiotensin Converting Enzyme II Inhibitor (ACE-I) is first line • Renal protective • Angiotensin Receptor Blockers (ARB) can be used if patient fails or is intolerant to ACE-I

    35. Adjunctive Therapies (cont) Dislipidemia • Patients with type II diabetes have an LDL goal < 100 mg/dL • Weight loss • First line therapy: statins (i.e. atorvastatin, simvastatin, rosuvastatin etc.) • Fiber, omega-3 fatty acids (fish oils) can be used as adjunct therapy Antiplatelet agents • Consider starting daily low dose aspirin (81 mg) to prevent ischemic events

    36. Adjunctive Therapies (cont) • Smoking cessation • Regular Screening for Cardiovascular Diseases and Coronary Artery Disease • Depression/Stress/Anxiety/Other psychosocial conditions need to be screen for regularly • Diabetic neuropathies especially in extremities need to be screened for on a regular basis • Fastidious foot care • Regular foot exams (annually) • Eye exams • Monitor kidney function